You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
PNU 22394 hydrochloride
Biological Activity for PNU 22394 hydrochloride
PNU 22394 hydrochloride is a potent 5-HT2C agonist and partial 5-HT2A/5-HT2B agonist. Non-selective between 5-HT2 receptor subtypes (Ki values are 18, 18 and 66 nM for human recombinant 5-HT2C, 5-HT2A and 5-HT2B receptors respectively). Reduces food intake in rats following subcutaneous administration and displays anorexigenic effects in humans.
Technical Data for PNU 22394 hydrochloride
|Storage||Desiccate at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for PNU 22394 hydrochloride
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for PNU 22394 hydrochloride
The following data is based on the product molecular weight 236.74. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||4.22 mL||21.12 mL||42.24 mL|
|5 mM||0.84 mL||4.22 mL||8.45 mL|
|10 mM||0.42 mL||2.11 mL||4.22 mL|
|50 mM||0.08 mL||0.42 mL||0.84 mL|
Product Datasheets for PNU 22394 hydrochloride
References for PNU 22394 hydrochloride
References are publications that support the biological activity of the product.
McCall et al (2001) PNU-22394, a 5-HT2C receptor agonist, reduces feeding in rodents and produces weight loss in humans. Soc.Neurosci.Abstr. 27 309
Jensen et al (2013) Design, synthesis and pharmacological characterization of N- and O-substituted 5,6,7,8-tetrahydro-4H-isoxazolo[4,5-d]azepin-3-ol analogues: novel 5-HT2A/5-HT2C receptor agonists with pro-cognitive J.Med.Chem. 56 1211
If you know of a relevant reference for PNU 22394 hydrochloride, please let us know.
View Related Products by Product Action
Keywords: PNU 22394 hydrochloride, PNU 22394 hydrochloride supplier, 5-HT2C, agonists, 5-HT2A/2B, partial, Serotonin, Receptors, 5-HT2, 5-HT2A, PNU22394, hydrochloride, 2201, Tocris Bioscience
Citations for PNU 22394 hydrochloride
Citations are publications that use Tocris products.
Currently there are no citations for PNU 22394 hydrochloride. Do you know of a great paper that uses PNU 22394 hydrochloride from Tocris? Please let us know.
Reviews for PNU 22394 hydrochloride
There are currently no reviews for this product. Be the first to review PNU 22394 hydrochloride and earn rewards!
Have you used PNU 22394 hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
5-HT Receptors Scientific Review
Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.